The proposal would expand coverage of anti-obesity drugs to 7.5 million people covered by Medicare and Medicaid, the Biden administration said.

Medicare and Medicaid would cover weight-loss drugs like Wegovy and Ozempic under a new rule proposed by President Joe Biden on Tuesday, increasing access to the widely popular medications to millions of adults with obesity in the U.S., though the plan would likely face opposition under President-elect Donald Trump's second administration.

President Joe Biden’s proposal to have GLP-1 weight-loss drugs such as Ozempic and Mounjaro covered by Medicare and Medicaid would help tackle the public-health crisis of obesity, but it would raise the costs for the government programs by billions of dollars per year.

The Biden administration on Tuesday proposed requiring Medicare and Medicaid to cover weight loss drugs like Wegovy and Ozempic. Why it matters: The rule would expand access to the medications for millions of Americans struggling with obesity,

Medicare and Medicaid would be required to cover weight loss drug prescriptions for millions of obese Americans under plans announced by the Biden administration Tuesday.

Under a new proposal from President Biden, weight loss drugs would be covered by Medicare and Medicaid. NBC News medical contributor Dr. Natalie Azar joins José Díaz-Balart to provide insight on who would benefit from the expanded coverage and what the approval process would look like.

If the proposal is finalized, it could set the stage for a showdown between the pharmaceutical industry and the Trump administration.

Millions of Americans with obesity would be eligible to have popular weight-loss drugs like Wegovy or Ozempic covered by Medicare or Medicaid under a new rule the Biden administration proposed.